Vertical sleeve gastrectomy and semaglutide have distinct effects on skeletal health and heart function in obese male mice
Caroline C. Picoli, S. Yu. Tsibulnikov, Mandy Ho, Victoria DeMambro, Tiange Feng, May Eltahir, Phuong Le, Carolyn Chlebek, Clifford J. Rosen, Sergey Ryzhov, Ziru Li
Abstract
Comparative studies of surgical and pharmaceutical approaches to weight loss offer critical insights that can guide clinical decision-making for managing obesity. VSG and semaglutide exhibit comparable efficacy in promoting weight reduction and improving glucose metabolism. VSG reduces energy expenditure, whereas semaglutide increases animal activity during nighttime. VSG leads to significant bone loss, whereas semaglutide preserves bone mass independent of weight loss. VSG improves cardiac outcomes, whereas semaglutide transiently affects heart function.
Topics & Concepts
SemaglutideMedicineWeight lossInternal medicineEndocrinologySleeve gastrectomyLean body massObesityCardiologyDiabetes mellitusType 2 diabetesBody weightLiraglutideGastric bypassBariatric Surgery and OutcomesDiet and metabolism studiesMetabolism, Diabetes, and Cancer